Medical Therapeutics for the Treatment of Vascular Anomalies: Part 3
Related Experiment Video
Updated: Jul 12, 2025

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
1Division of Hematology, Cancer and Blood Diseases Institute, Hemangioma and Vascular Malformation Center, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 7015, Cincinnati, OH 45229, USA; University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0558, USA.
Abstract:
The discovery of inherited and somatic genetic mutations, along with advancements in clinical and scientific research, has improved the understanding of vascular anomalies and changed the treatment paradigm. With the aim of minimizing the need for invasive procedures and improving disease outcomes, molecularly targeted medications and anti-angiogenesis agents have become important as both adjuncts to surgery, and increasingly, as the primary treatment of vascular anomalies. This article highlights the commonly used and emerging therapeutic medications for nonmalignant vascular tumors and vascular malformations.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Aneurysm III: Interprofessional Care
Atherosclerosis III: Management
Aortic Regurgitation III: Medical Management
Venous Thrombosis III: Interprofessional Care
Regulation of Angiogenesis and Blood Supply

